glp-1 drugs for obesity Agonists: Using Semaglutide, Tirzepatide, and Orforglipron Weight Loss and The Impact of GLP-1 on
Description
Retrieved from NovoNordisk-a
Y., In Vivo Challenges of AntiDiabetic Peptide Therapeutics: Gastrointestinal Stability, Toxicity and Allergenicity, Trends in Food Science and Technology 105 (2020): 161175
2011 Jul;34(7):1041-3
Weight change after GLP-1 discontinuation in US patients living with overweight/obesity or diabetes
doi: 10.1111/gtc.12884 14 KanberDGiltayJWieczorekDZogelCHochstenbachRCaliebeAet al
